Your SlideShare is downloading. ×
Personalised Medicine and Diagnostics 2011
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Personalised Medicine and Diagnostics 2011

1,336
views

Published on

Innovate in an era of cost-effectiveness: Realise the value of personalised medicine …

Innovate in an era of cost-effectiveness: Realise the value of personalised medicine
• How is your business model evolving? Transform from Blockbuster to Nichebuster
• Discover how to strengthen your drug pipeline with companion diagnostics
• How to access the market
• Hear about the expectation of the pharmaceutical and diagnostics industry and payors
• Discover how pharmaceutical companies and diagnostics companies can work together successfully

Powerful reasons to attend the event:
Get the latest information on personalized medicine at your fingertips.
With access to exclusive keynote sessions and a very focused agenda, you’ll gain more in just 2 days than from weeks of market research or by purchasing expensive reports.

Expert speakers from Roche, Merck, Biomerieux, NICE, Pfizer and GSK will share their vision and best practice case studies. You can really profit from their knowledge and create powerful new strategies to overcome your business challenges.

Unrivalled networking.

Claim your seat at the table with all the key industry decision-makers and thought leaders to ensure you leave this meeting with your briefcase full of valuable contacts. Plus benefit from a number of structured 1-1 meetings during the networking breaks.

Senior level decision-makers in attendance.
Rub shoulders with the leading executives in personalized medicine from the U.S. and around the world to give your commercial enterprise a truly global perspective.

No sales pitches.

Personalized Medicine & Diagnostics is an independently researched forum committed to equip you with the tools and expertise to drive your business forward. Every single presentation is rigorously reviewed to ensure an unrivalled high quality.

Published in: Business

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,336
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
28
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. europe’s premier meeting that brings together the pharmaceutical Save € 200 orGAnIsed & reseArched By and diagnostics industry WhEn you rEgiStEr bEforE 28th January 2011pErSonaliSEd MEdicinE& diagnoSticS EuropE9-10 March 2011, novotel london St. pancras, ukinnovate in an era of cost-effectiveness: realise the value ofpersonalised medicine3 How is your business model evolving? Transform from Blockbuster ExpErt SpEakErS to Nichebuster AndreA rAppAGlIosI Vice president european Government Affairs,3 How to take advantage of the economic and business trends in gSK and president, personalised medicine europaBio hAns wInkler3 Strengthen your drug pipeline with companion diagnostics senior director, head of oncology Biomarker development, ortho Biotech oncology,3 Overcome the challenges in regulation and market access Johnson and Johnson3 Hear about the expectation of the pharmaceutical and diagnostics Pharmaceutical industry and payors IAIn d. mIller executive director, theranostics strategy and Business development,3 Discover how pharmaceutical companies and diagnostics companies can work together successfully Biomerieux Glyn coleBrooke senior director, CONfereNCe 3 TOPICS & SPeAKerS 3 NeTwOrKINg 3 Business development, senior level executives from we listen to what the industry during the 12+ hours of dedicated Philips the most relevant sectors come wants. the program of the event networking, you’ll rub shoulders together for exclusive keynote was structured in conjunction with with the sharpest minds in AdAm heAthfIeld sessions, case reports and high senior level executives to make it the industry. no other event director science policy, level business discussions that will as applicable and useful as possible. can provide you with 2 days of set the pace of future therapeutics. the best qualified speakers will business focused networking Pfizer be sharing their knowledge and with some of the most influential experience with you! people in your field. nIck crABB Associate director, diagnostics Assessment programme An excellent conference which delivered what Centre for Health Technologyit said on the tin! evaluation, NICecAthArIne GoddArd,principal translational scientist, Pfizer Good meeting,In AssocIAtIon wIth: perfect number of delegates, excellent discussion and interactions JAmes clArk MDx HealthoffIcIAl medIA pArtner: medIA pArtners:
  • 2. welcome to personalised medicine & diagnostics europeDear Colleague …our global business intelligence has revealed widespread 3 out who “big pharma” is partnering with and why find personalised medicine & diagnostics europe is a land-pressure to streamline, increase operational output and showcase of latest technology 3 mark on the industry calendar and a priority for allreduce costs. the pharmaceutical industry has received professionals serious about the future of drug develop-a call to action! translating findings across the value As diagnostics expert who wants to diversity your prod- ment with companion diagnostics.chain and sub-grouping patients can deliver proven uct portfolio and take advantage of this fast growingroI, and is the biggest area of growth in the healthcare sector you will find out how to partner with pharma- Personalised Medicine & Diagnostics europe is thesector. so what’s holding personalised medicine back ceutical companies and what they are looking for. only event you’ll need to attend in 2011!and when will mass adoption become a reality? so secure a front row seat for an unobstructed view of Personalised Medicine & Diagnostics europe the future of the pharmaceutical industry! reserve yourIn 2011, we have produced an agenda that will prepare boasts of: place today (via our website or the registration form en-you for the new era of personalised medicines. It has closed in this brochure). expert personalised medicine speakers from pharma, 3 been described as do-or-die for the pharma industry by I look forward to meeting you in london this march. biotech, diagnostics and regulatory agencies willsome experts. provide cutting-edge strategies and market intelligence 3 will discuss successful and failed cases to theyI have invited the most forward-thinking leaders from give you the toolkit for your successful productthe industry to discuss the roadmap to a strong industry development yours,growth.take a look at some key discussion points in 2011: meet the companies that are looking for partner- 3 Analysis of the personalised medicine market in3 ships and discover how you can work together europe and globally meet new solution providers who will present their 3 3 out what the value of companion diagnostics is find developments and technologies that help you with JohAnnes stAntA learn how to overcome market access hurdles for3 your challenging problems Ph.D., Vice President, personalised medicines and companion diagnostics Unparallel networking is the icing on the cake! 3 eyeforpharma jstanta@eyeforpharma.comexpert speakers include: Andrea rappagliosi stefan müllner louise leong Vice president european Government Affairs, ph.d., ceo, ph.d., head of r&d, Association of the British gSK and president Protagen Ag pharmaceutical Industry, ABPI europaBio Angela flannery charles swanton Glyn colebrooke ph.d., director, r&d science policy ph.d., head translational cancer senior director Business development AstraZeneca therapeutics, Cancer research UK Philips Adam heathfield pietro scalfaro matthew w. Beer ph.d., director science policy ph.d., director of Business Unit diagnostics, ph.d., managing director oncology marketing, Pfizer Debiopharm Quest Diagnostics hans winkler nick crabb eddie Blair ph.d., senior director, head of oncology Biomarker ph.d., Associate director, diagnostics Assessment ph.d., managing director, development, ortho Biotech oncology, programme, centre for health technology Integrated Medicines Johnson and Johnson Pharmaceutical r&D evaluation, NICe (national Institute for health and clinical excellence) michael motz Gabriel Vargas david Gonzalez de castro ph.d., director, m.d., ph.d., Biomarker expert at ph.d., head of molecular diagnostics, Business development and partnering, Hoffmann-La roche The royal Marsden Hospital and The Institute of roche & head of the CNS Clinical Biomarker group Cancer research Alexander natz John lambert James clark ll.m., secretary General, eUcope and head mBBs, ph.d, mmed, mfpm, frAcp, Vice president ph.d., Vice president research and development, of Brussels office, Bundesverband der chief medical officer early phase clinical Unit, MDx Health Pharmazeutischen Industrie e.V. (BPI) Parexel Iain d. miller Ansar Jawaid paolo morgese executive director, theranostics strategy and ph.d., Global diagnostics Brand manager, Associate director, market Access, Business development, Global commercial, MerckSerono Biomerieux AstraZeneca for the full speaker line-up and the most up to date information visit www.eyeforpharma.com/personalisedmedicine
  • 3. personalised medicine & diagnostics europe at a Glance 3 1-2-1 COLLABOrATION MeeTINgS In addition to providing a programme that is designed to give delegates plenty of information that will help them solve their business challenges, the event will also include an option for Good meeting, the per- delegates to take part in a number of structured 1:1 ‚matchmaker‘ or collaboration meetings. fect number of delegates, excellent discussion and 3 interactions. CONfereNCe JAmes clArk, MDx Health Personalised Medicine & Diagnostics europe, 9th - 10th March, Novotel London St. Pancras, UK New fOr 2011 DAy ONe – 9th mArch 2011 DAy TwO – 10th mArch 2011 3 A best practice guide on integrating MOrNINg OPeNINg KeyNOTe AND SeSSION 3: diagnostics in the drug development PLeNAry SeSSIONS BUSINeSS MODeLS THAT ACHIeVe THe process hear where the industry is moving and get DeVeLOP PerSONALISeD MeDICINe the latest updates PrODUCTS 3 companies that are looking for discover how to strengthen the drug partnerships SeSSION 1: pipeline with companion diagnostics and 3 the best speakers from the industry PerSONALISeD MeDICINe MArKeT how this trends is becoming a necessity OVerVIew 3 All vital industry topics examine major trends and learn where to - Networking Lunch - invest your efforts 3 more case studies about the good SeSSION 4: and the bad - Networking Lunch - ASSeSSINg, PrICINg AND reIMBUrSINg 3 what diagnostics companies need PerSONALISeD MeDICINe to provide to be seen a great partner SeSSION 2: focus your efforts on the right areas for the pharmaceutical industry INTegrATe COMPANION DIAgNOSTICS and find out what the emA and health IN THe DrUg DeVeLOPMeNT PrOCeSS technology Assessment departments are 3 networking with all key industry expecting players in personalised medicine - Networking Drinks Party - and companion diagnostics - Closing Address - 3 NeTwOrKINg AND exHIBITION face-to-face networking is key to survival The only exhibition floor you’ll need in 2011. you’ll rub shoulders with the the personalised medicine & diagnostics sharpest minds in r&d during the 12+ hours exhibition floor is an opportunity to see, discover of dedicated networking. no other event and understand new products and solutions in can provide you with 2 days of business action. spaces are limited. Get in touch today focused networking with some of the with richar ellis on +44 20 7375 7170 or most influential people in your field. Build rellis@eyeforpharma.com to secure your place. relationships and grow your contact list in 2011 to transform the future of your business. Join our lively conference group on and become a part of the global buzz surrounding the conference.
  • 4. day 1: wednesday march 9th 2011sessIon 1: Accelerate drug development through the role of efficacy biomarkers in drug-Personalised medicine market confident and data-based decision diagnostics co-development programsoverview making 3 how to strengthen the drug pipeline with 3 Increase likelihood of clinical benefit: experiences companion diagnostics and how this trends isAn initiative for stratified medicines and strategies in data-driven patient selection becoming a necessity based on predictive biomarkers. 3 discuss the challenges of companion diagnostics3 the future of personalised medicine in europe 3 Best ways to master the critical issue in the devel- development in central nervous system diseases3 what is the Uk government plan to create an opment process: assessing clinical efficacy of novel and how to approach them environment in which the industry can flourish and medicines early. grow and how that will transform the european 3 discuss the key factors in translational science for an Gabriel Vargas, m.d., ph.d., Biomarker expert & head industry? efficient diagnostics co-development of the cns clinical Biomarker Group, Hoffmann-La3 learn how public and private partnership could roche lead to an integrated approach to tackle the issues hans winkler, ph.d., senior director oncology of uptake and reimbursement Biomarkers, Janssen Pharmaceutical Companies of dnA methylation patterns in cancer Johnson & JohnsonAngela flannery, ph.d., director, research and research and the use in companiondevelopment science policy, AstraZeneca diagnostics how to use biomarkers in early clinical drug development to support person- 3 learn about the challenges in cancer analytics and alised medicine strategy diagnostics development and how mdx health issessIon 2: addressing these 3 Identify the key factors for translational science in 3 discuss how dnA methylation in cancer discoveryIntegrate companion diagnostics diagnostics development and prediction can overcome common problems inin the drug development process 3 learn to use the best strategies to maximise the pharmacogenomics value of biomarkers and strengthen your develop- ment pipeline James clark, ph.d., Vice president research andprovide efficient molecular diagnostics 3 hear about successful cases in molecular diagnos- development, MDx Healthand molecular pathology service for tics and how to move from technologies tocancer patients treatments3 learn what is required to implement molecular John lambert, mBBs, ph.d, mmed, mfpm, frAcp, Vice sessIon 3: diagnostics in the clinic3 the challenges of molecular diagnostics in routine president chief medical officer early phase clinical Business models that achieve the Unit, Parexel real-life practice in the Uk and how the royal development of personalised marsden hospital has found solutions in a wide port folio of personalised cancer medicines medicine products digital histopathology stratified medi-3 the future directions of molecular pathology and clinical trials. horizon mapping cine and robust companion diagnostics. deliver personalised medicines to the patientdavid Gonzalez de castro, ph.d., head of molecular 3 Assessment of tissue architecture as the entry pointdiagnostics, The royal Marsden Hospital and for personalising cancer treatment 3 learn how to develope and deliver a global diag-The Institute of Cancer research (ICr) 3 discover how digital management of histopatho- nostic strategy on the example of Astrazeneca’s logy images introduces the opportunity to improve oncology drugs accuracy, collaboration, reporting and archiving 3 discuss practical initiatives that have driven 3 new digital systems allow for automated high diagnostic testingovercome challenges in cancer throughput histopathology on a platform that have 3 find out how to meet the needs of differentmedicine biomarker discovery a straightforward journey from discovery to clinical countries to successfully launch a personalised practice medicine globally3 discover the reasons for limited examples of pre- dictive biomarkers in oncology practice and how Glyn colebrooke, senior director Business Ansar Jawaid, ph.d, Global diagnostics Brand manager, to overcome this development, Philips global Commercial, AstraZeneca3 discuss how functional genomics can be integrated with parallel clinical trials to accelerate biomarker Using autoantibodies in companion discovery3 the major challenges to personalised medicine diagnostics and predictive biomarker discovery in cancer research – can a multi-disciplinary collaborative 3 Autoantibodies vs. genomic based markers in approach address this? patient stratification and therapy selection: the superiority debatecharles swanton, ph.d., head translational cancer 3 A new concept: Autoantibody signatures for thetherapeutics, Cancer research UK development and validation of dx and cdx marker panels stefan müllner, ph.d., ceo, Protagen
  • 5. day 2: thursday march 10th 2011successful strategies in personalised INTerACTIVe PANeL SeSSION: INTerACTIVe PANeL SeSSION:medicine: learnings from a global IVd how to align business models and development what constitutes value in a companion diagnostic?company time-lines between pharmaceutical and diagnostics companies Anne Bruinvels, ph.d., executive director, 3 3 discover the strategic perspective on the personal- 3 matthew w. Beer, ph.d., director oncology european Personalised Medicine Association ised medicine market from an IVd viewpoint marketing, Quest Diagnostics 3 crabb, ph.d., Associate director, nick3 discuss successful co-development and alliance 3 eddie Blair, ph.d., managing director, Diagnostics Assessment Programme, NICe management models in cancer and infectious Integrated Medicines paolo morgese, Associate director, 3 disease 3 Angela flannery, ph.d., director, research and market Access, MerckSerono3 Gain inisight into how Biomerieux made successful development science policy, AstraZeneca partnerships with Gsk, merck, Ipsen, and transgene to mutually benefit all stakeholders sessIon 4: sessIon 5:Iain d. miller, ph.d., executive director, theranostics The challenges of assessing, Make partnering work across thestrategy and Business development, Biomerieux pricing and reimbursing industry personalised medicinethe evolution of an alternative business how to effectively interface molecularmodel in the pharmaceutical industry changes in the German market diagnostic during drug development to for pricing and reimbursement of prepare for personalised medicine3 Identify the key factors for moving from technolo- gies to treatments to stay at the forefront of the innovative pharmaceuticals 3 Best ways to find key capabilities to make optimal industry 3 learn who are the key players in the German market and evidence based decisions3 learn about the emerging diagnostics areas to focus 3 discover what will happen with the German htA 3 pitfalls of data-based decision making and using your efforts in the areas with the highest potential and which impact the early benefit assessment quality of data over quantity3 discuss cases of pre-and post-approval collabo- under § 35a sGB V will have on your market access 3 how to manage the partnering expectations to rations to make evidence based decisions in your strategy. ensure shared vision and values and to get the right partnering strategies 3 hear about the pitfalls in price negotiations and the balance of time, quality and cost impact of reference pricingmatthew w. Beer, ph.d., director oncology marketing, pietro scalfaro, m.d., director Business Unit diagnostics,Quest Diagnostics Alexander natz, ll.m., secretary General, eUcope and Debiopharm group head of Brussels office, Bundesverband derhow to ensure long term success in Pharmazeutischen Industrie e.V. (BPI) work on an unified strategy fordelivering personalised medicine personalised medicine the nIce diagnostics assessment3 Investigate best strategies for the co-development of drugs and diagnostics and hear what has worked programme 3 learn how the formation of new r&d partnerships has transformed the outlook for personalised and what hasn’t 3 learn about nIce and the new diagnostics medicine in the Uk3 partnership trends in the industry and what roche Assessment programme 3 Get a deep dive and analysis of partnerships that is looking for in a strategic partner and diagnostics 3 discuss the methodology challenges in the assess- have been consummated co-developer ment of clinical and cost effectiveness of diagnostic 3 hear about the role of clusters in fostering partner technologies ship in personalised medicine, including case studiesmichael motz, ph.d., director, Business development 3 hear about nIce’s view on the assessment ofand partnering, roche companion diagnostics louise leong, head of research and development, Association of the British Pharmaceutical Industrypersonalised medicine in a era of cost- nick crabb, ph.d., Associate director, diagnostics (ABPI)effectiveness Assessment programme, National Institute for Health and Clinical excellence (NICe)3 what are the challenges in adding diagnostics to philippe mourere, Caliper Life Sciences, clinical practice and do medicines developers the european policy agenda in (about personalised medicine Us 2010) benefit from it? personalised medicine3 discuss the importance of diagnostics for commer- cial and research success 3 what is on the agenda of the european commission3 what pfizer has learned from personalised medicine and how will it effect personalised medicine? The speakers selection experiences to date and the impact on research, 3 focus your efforts on the right areas and find out cost, time of development and commercialisation what the emA and health technology Assessment was great - covered theAdam heathfield, ph.d., science policy director, Pfizer departments have planned. promises and challenges 3 can the transparency directive support the improvement of access to personalised medicine? of personalised medicine Andrea rappagliosi, Vp european Government strategies in the discovery Affairs & head of Brussels office, gSK. and diagnostic areas. chair of the europaBio Healthcare Council
  • 6. key reasons why you can’t miss the conferenceknoW Who you’ll bE rubbing ShouldErS With in March 2011Attendees by Industry sector:SPLIT By SeCTOr: SPLIT By JOB TITLe: media other consultant 3% 8% ceo/president/Vice 5% president director Academia 11% 26% 14% Industry manager (pharmaceutical, Biotechnology & 16% technology diagnostics) provider/cro 15% 63% head scientist/researcher 21% 18%Industry sectors: Pharmaceutical, biotech, diagnostic diagnostic Biomarker Business companion development health research development diagnostics economics new products & portfolio strategy regulatory who’s attending? Affairs personalised therapy strategic scientific/medical market Access partnering Affairs research scientistTop reasons to become a sponsor of Personalised Medicine & Diagnostics today! promote your technology in a show-case presentation or a full speaking slot and be3 part of the program3 up now to secure the best booth on the expo floor and give your products and sign Join our dedicated services the competitive edge. meet directly with your best prospects and clients. personalised medicine & diagnostics3 LinkedIn group at europe is the event where industry leaders make informed decisions.3 up early to capitalised on pre-event visibility via our network of key industry sign www.linkedin.com players to guarantee that everyone talks about you. don’t forget that personalised medicine & diagnostics europe is the place where new3 relations are forged and partnerships start. grOUP SeArCH:3 the right thing for your company and book your space now before the exhibition do eyeforpharma Translational Medicine space sells-out. Innovation contact richard ellis today to get your quote at rellis@eyeforpharma.com or +44 20 7375 7170
  • 7. three simple steps to register now!Staying in london?we want to invite you to extend your stay inlondon either before or after the summit, andyou are more than welcome to bring a partner.we’ve negotiated special rates in the novotel st.pancras for you. for further information on howto book, visit the venue page on our websitewww.eyeforpharma.com/personalisedmedicineSeLeCT PASS TyPe PHArMA, BIOTeCH & DIAgNOSTICS COMPANIeS SUPer eArLy BIrD eArLy BIrD STANDArD PrICe register by 17.12.2010 register by 28.01.2011 PLATINUM PASS € 1895 + VAt € 2095 + VAt € 2295 + VAt 3 day full access pass two 3 event recordings full 3 report on personalised medicine gOLD PASS € 1695 + VAt € 1895 + VAt € 2095 + VAt 3 day full access pass two 3 event recordings full SILVer PASS € 1495 + VAt € 1695 + VAt € 1895 + VAt 3 day full access pass two ACADeMIA AND gOVerNMeNT € 995 + VAt € 995 + VAt € 995 + VAt SOLUTION PrOVIDerS & CONSULTANTS SUPer eArLy BIrD eArLy BIrD STANDArD PrICe register by 17.12.2010 register by 28.01.2011 PLATINUM PASS € 2095 + VAt € 2295 + VAt € 2495 + VAt 3 day full access pass two 3 event recordings full 3 report on personalised medicine gOLD PASS € 1895 + VAt € 2095 + VAt € 2295 + VAt 3 day full access pass two 3 event recordings full SILVer PASS € 1695 + VAt € 1895 + VAt € 2095 + VAt 3 day full access pass two DISCOUNT CODe:Mr/Mrs/Ms/Dr: first name: Last name:Company Position/Title:Telephone: fax: email:Address: Postcode: Country: Credit Card Number: I enclose a check/draft for: expiry date: Security number: (Payable to fC Business Intelligence) Name on card: Please invoice my company: Purchase Order number: Signature: Please charge my credit card: Amex Visa Mastercard fax this form back to +44 (0) 20 7375 7576TerMS AND CONDITIONS places are transferable without any charge i.e. you can change the name of the attendee for the organizers reserve the right to make changes to the program without notice. All prices displayed are exclusive of tax unless otherwisefree. cancellations before 9th february 2011 incur an administrative charge of 25%. If you cancel your registration after 9th stated. tax will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice.february 2011 we will be obliged to charge you the full fee. please note - you must notify eyeforpharma in writing (email) of a eyeforpharma takes every care to ensure that prices quoted are correct at time of publishing however, bookings will only be accepted if therecancellation, or we will be obliged to charge you the full fee. is no material error in the price advertised on the website.
  • 8. europe’s premier meeting that brings together the pharmaceutical Save € 200 orGAnIsed & reseArched By and diagnostics industry WhEn you rEgiStEr bEforE 28th January 2011pErSonaliSEd MEdicinE& diagnoSticS EuropE9-10 March 2011, novotel london St. pancras, ukinnovate in an era of cost-effectiveness: realise the value ofpersonalised medicinepowerful reasons to attend: industry buzz about eyeforpharma’s1 6 MONTH’S reSeArCH with executives from the top 20 pharma and diagnostics companies like pfizer, AstraZeneca, novartis, roche, Biomerieux have ensured we know exactly what yoU need to know when it comes to to succeeding in the past personalised and translational medicine conferences: “Well worth the money” growing market of personalised medicine. Jonathan sheldon, IDBS2 exPerT SPeAKerS. the leading minds and key opinion leaders from roche, merck, Biomerieux, nIce, pfizer, Gsk will share their vision and best practice case studies. you can really profit from their knowledge and create powerful new strategies to overcome your business challenges. “An excellent conference which deli- vered what it said on the tin!” catharine Goddard, Pfizer “Great event!”3 doina roman, Takeda global r&D UNrIVALLeD NeTwOrKINg. claim your seat at the table with all the key industry decision-makers and thought leaders to ensure you leave this meeting with your “An interesting meeting with briefcase full of valuable contacts. plus benefit from a number of structured good content and good networking opportunities” 1-1 meetings during the networking breaks. mads Almose røpke, LeO Pharma4 SeNIOr LeVeL DeCISION-MAKerS IN ATTeNDANCe. rub shoulders with the “I appreciated the openness and leading executives in drug development from europe and around the world to interactivity of the sessions” Inge de lepeleire, give your commercial enterprise a truly global perspective. Merck Sharp & Dohme, Inc.5 NO SALeS PITCHeS. personalised medicine & diagnostics medicine is an “Well organised, high level and independently researched forum committed to equip you with the tools and interesting programme. Good speakers.” expertise to drive your business forward. every single presentation is rigorously elina serkkola, Orion Pharma reviewed to ensure an unrivalled high quality. 4 EaSy WayS to New fOr 2011 In addition to providing a programme that is designed to give delegates plenty rEgiStEr Call +44 (0) 20 7375 7225 of information that will help them solve their business challenges, the event fax +44 (0) 20 7375 7576 will also include an option for delegates to take part in a number of structured email register@eyeforpharma.com 1:1 collaboration meetings. Online www.eyeforpharma.com/ personalisedmedicineIn AssocIAtIon wIth: offIcIAl medIA pArtner: medIA pArtners: